CTOs on the Move

Day One Biopharmaceuticals

www.dayonebio.com

 
Day One Biopharmaceuticals understands that advances in cancer research now enable drug developers to identify children and adults who may benefit from the same medicine.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.dayonebio.com
  • 395 Oyster Point Blvd Suite 217
    South San Francisco, CA USA 94080
  • Phone: 650.770.9034

Executives

Name Title Contact Details

Funding

Day One Biopharmaceuticals raised $60M on 05/21/2020
Day One Biopharmaceuticals raised $130M on 02/10/2021

Similar Companies

AC Immune

AC Immune SA, a global leader in developing precision medicine for neurodegenerative diseases (incl. Alzheimer & Parkinsons) with cutting-edge technology platforms

Noveome Biotherapeutics

Noveome Biotherapeutics, Inc. is a clinical stage company focused on breakthrough therapies for the regenerative repair of inflamed or damaged tissues.

Seisa Medical

Seisa Medical is a El Paso, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Enzon Pharmaceuticals Inc.

Enzon Pharmaceuticals Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Aruvant

Aruvant`s mission is to bring hope to patients living with rare diseases by developing life changing and potentially curative gene therapies, with a near-term focus on sickle cell disease. Aruvant is a part of the Roivant family of companies. We have a talented team with extensive experience in the development, manufacturing and commercialization of gene therapy products. We have an active research program with a lead product candidate in development for individuals suffering from sickle cell disease (SCD). Our lead product candidate, ARU-1801, an investigational lentiviral gene therapy, is currently in a clinical trial as a potential one-time curative treatment for SCD. Preliminary clinical data from the ongoing Phase 1/2 study demonstrated durable efficacy in reducing the negative impacts of SCD. We are preparing for the launch of our pivotal clinical trial in SCD. We continue to look for new people to add to our talented team.